AVESTHAGEN LIMITED

A frontier company in medical genetics research

DNA Link is currently in collaboration with Korea’s most renowned clinical research specialists studying genetic effects of various diseases including diabetes, cardiovascular disease, cancer, atopy, and digestive diseases.

Recent advancements in genomic research technology have enabled rapid analysis of whole genomes. Our current research projects utilize this technology to identify relationships between diseases and genomic content.

In the past, genetic disease studies were conducted using a finite set of candidate genes as targets for research. While the results were valuable, the success of this approach was limited because diseases can depend on multiple factors, genetic and environmental. Modern genetic research methodologies take a more extended approach, considering the entire human genome to search for potential disease markers.

In addition to identifying disease-related genes, DNA Link is working to develop disease diagnostic systems as well as personalized treatment methods. Using DNA Chip and Next Generation Sequencing technologies, we are currently developing cancer diagnostic systems by identifying common variants in DNA copy numbers for various cancers including lung cancer and breast cancer

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2

Holypharm Biotech specialized in active pharmaceutical ingredients and intermediates. With our head-office in the capital of Zhejiang Province: Hangzhou. We have participations and contracts with 2 plants located Zhejiang and Jiangsu Province. Our main products are cardiovasculars, antidiabetes, anti-cancer. Our products have been registered in Latin America, India, North-America, Turkey, etc..

To provide clients with more technology support, we will present efficient regulatory documents to show professional abilities in this field. We are experts in quality control, registration data, excellent packaging & labeling and logistics.

HOLYPHARM (PHARM DEPT.) - Our main products are cardiovasculars, antidiabetes, anti-cancer, steroid, antibiotics, anti-HIV and their intermediates, especially on cardiovascular and antibiotics.

HOLYPHARM (VETERINARY DEPT.)-All our manufacture bases and facilities are GMP approved, we provide more than 100 veterinary products, forms including raw material ( ferment and synthesize products), premix, injection, tablets, suspension etc..

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 166 million company, employs over 6000 people including over 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, DRU Botswana, PMDA-Japan, TGA-Australia, FMHACA-Ethiopia, DPML- Ivory Coast, SAHPRA- South Africa, NDA-Uganda, etc.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals,  Cardiovascular, Anti-Diabetics, Pain Management  etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital,  Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM, Methycal, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Indoco has carved a place for itself in the international arena and is exporting a number of generic products in the Regulated and Emerging Markets. Indoco’s branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS countries. The Company participates in various tenders floated by authorities from different countries. Indoco has tie-ups with large generic companies across the globe and works in close coordination with its customers for leveraging core competencies.

Indoco Analytical Solutions division has been carved to serve customers for their analytical research needs. AnaCipher CRO, Hyderabad, is a USFDA inspected facility providing clinical trial solutions, BA/BE/Phase I/Phase studies.